Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
NCT05859048

Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Led by Cardiology Research UBC · Updated on 2024-03-07

1360

Participants Needed

3

Research Sites

252 weeks

Total Duration

On this page

Sponsors

C

Cardiology Research UBC

Lead Sponsor

A

AstraZeneca

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure. The main question\[s\] it aims to answer are: • will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care? Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm: SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure. Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months

CONDITIONS

Official Title

Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female over 40 years of age
  • Able to provide informed consent
  • Have at least two of the following risk factors for heart failure:
    • Coronary artery disease (previous heart attack, bypass surgery, stenting, or significant artery narrowing)
    • Type 1 or type 2 diabetes
    • Persistent or permanent atrial fibrillation
    • Previous ischemic or embolic stroke
    • Peripheral artery disease (prior revascularization or significant artery narrowing)
    • Chronic kidney disease with specific kidney function or urine test results
    • Regular use of loop diuretics for more than 30 days within the past year
    • Chronic obstructive pulmonary disease (COPD) diagnosed by lung tests, physician, scans, or treatment
Not Eligible

You will not qualify if you...

  • Unable to give informed consent due to cognitive impairment
  • Previous diagnosis of heart failure of any type or cause
  • Receiving renal replacement therapy
  • Any condition that the investigator believes makes participation unsuitable, such as limited survival over the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Vancouver General Hospital

Vancouver, British Columbia, Canada, V5Z 1M9

Actively Recruiting

2

Montreal Heart Institute

Montreal, Quebec, Canada, H1T 1C8

Not Yet Recruiting

3

University of Sherbrooke

Sherbrooke, Quebec, Canada, J1H 5N4

Not Yet Recruiting

Loading map...

Research Team

N

Naomi Uchida, BSN

CONTACT

J

Jennifer Petterson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SCREENING

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure | DecenTrialz